Here's a few CLL related updates on the COMPLEMENT 2 trial - ofatumumab with fludarabine and cyclophosphamide (OFC), the PI3Kδ/γ inhibitor duvelisib (IPI-145), TGR-1202 a next-generation PI3kδ and a novel SYK (Spleen tYrosine Kinase) inhibitor TAK-659, from Hematology Times (free membership).
From the 20th Congress of the European Hematology Association (EHA):
OFC Combo delays progression in relapsed CLL
Results of the COMPLEMENT 2 trial indicate that adding ofatumumab to treatment with fludarabine and cyclophosphamide (OFC) can improve some outcome measures in patients with relapsed chronic lymphocytic leukemia (CLL), when compared to fludarabine and cyclophosphamide alone (FC)
PI3Kδ/γ inhibitor duvelisib (IPI-145) generates rapid responses in CLL
New research indicates that duvelisib, a dual inhibitor of PI3Kδ and PI3Kγ, can generate rapid partial responses in treatment-naïve patients with chronic lymphocytic leukemia (CLL)
From the 13th International Conference on Malignant Lymphoma (ICML):
‘Radically different’ PI3Kδ inhibitor TGR-1202 lacks hepatotoxicity
Updated phase 1 results with TGR-1202 suggest this next-generation PI3kδ inhibitor lacks the hepatotoxicity associated with other PI3Kδ inhibitors
Novel SYK inhibitor TAK-659, shows ‘good early evidence’ of activity
The phase 1, first-in-human study of the novel SYK inhibitor TAK-659 is showing “good early evidence” of antitumor activity in patients with lymphoma, according to investigators.